News About: Pharm. Industry
Two foreign vaccine firms hit by administrative dispositions
The Korea Food and Drug Administration announced on November 23 that it meted out a certain amount of fines (corresponding to sales ban for fourth months) to two foreign-invested pharmaceutical firms each for falsely ...
Domestic pharmaceutical industry likely to gain steam in 2005
Korean pharmaceutical industry is expected gain momentum next year due to favorable business performance of major pharmaceutical firms, less regulatory pressure and visible outcome of R&D new drug projects, said a loc...
Proportion of flagship products seen increasing
Despite the sagging economy, the share of leading OTC products in the total sale of pharmaceutical firms (FY: December) in the third quarter of this year stood at more 10 percent, thus significantly improving the bala...
CKD to conduct Phase I trial for novel antidiabetic agent
The Ministry of Health and Welfare said on November 22 that Chong Kun Dang Pharmaceutical Co. will conduct its Phase I trial for novel glitazone-based diabetes medication (code name: CKD-501) with the ministry's finan...
Slowdown in OTC sector
Influenced by a compulsory bioequivalence testing requirements dictated by the government this year, the number of newly approved ethicals during August-October period stood at 712, or 90 percent of the 770 it...
Conglomerates to enter a chain drug store business
The retail pharmacy and chain drug store business seems to be unlimitedly competitive among the conglomerates amid the market opening of the retail pharmacy business and permission of a corporate type of pharmacy prac...
Yuhan Corporation to open mammoth R&D center in 2005
Yuhan Corporation held a ground-breaking ceremony to mark its large R&D center in Kiheung of Yongin City, Kyunggi Province on November 17.
For the company, the R&D lab would expand its research programs to a variet...
Many drug makers to seek price hike of flagship drugs
Largely influenced by the prolonged economic slump and protracted high oil price trend, an increasing number of drug makers are moving to increase the prices of some flagship products, such as pain-killers or digestiv...
Daewoong introduces Tillots's Asacol in Korea
Daewoong Pharm said it has launched Asacol (mesalazine) in the domestic market, which is the leading drug worldwide for the treatment of Inflammatory Bowel Disease (IBD). It signed a licensing agreement for the exclus...
Civil group demanding withdrawal of trademark Bacchus-S
A pharmacist group (http://cafe.daum.net/pharmmaker) has called on Dong-A Pharm to withdraw the possible use of a controversial trademark 'Bacchus-S', a quasi-drug, as it might lead an end-user to believe that Bacchus...
